Market news — every asset we track

Assets

Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504

Sep 27Yahoo Finance

Equillium at Stifel 2026 Virtual Immunology and Inflammation Forum: pipeline advances

Sep 23Investing.com

Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum

LA JOLLA, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will be participating in a fireside chat at Stifel’s 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23, 2026 at 12:00pm EDT. Members of the Equillium management team will be available to meet with investors who are registered to attend the conference. A

Sep 16Yahoo! Finance Canada

Equillium at Cantor conference: EQ504 advances as lead ahr program

Sep 11Investing.com

Equillium to Participate in Upcoming Investor Conferences

LA JOLLA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2026Format: Fireside Chat & 1x1 MeetingsDate: Wednesday, September 9, 2026Time: 9:45 AM EDTWebcast Link: Here H.C. Wainwright 28th Annual Global Investment ConferenceFormat: Co

Sep 2Yahoo Finance

Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter Cash and cash equivalents of $57.2 million expected to fund operations into 2029 LA JOLLA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders, today reported financial results for the second quarter end

Aug 13Yahoo Finance

Analysts Are Bullish on These Healthcare Stocks: Equillium (EQ), CSL (CMXHF)

Tipranks Press Release.

Jul 25The Globe and Mail

Equillium: The Market Seems To Have Already Priced In Phase 1 Success (NASDAQ:EQ)

Jul 22Seeking Alpha

Clear Street initiates Equillium stock with buy rating on IBD drug potential

Jul 21Investing.com

Piper Sandler initiates Equillium stock with overweight rating

Jul 13Investing.com

This is the newest page. Registered accounts read further back.